*BI-1208.10



Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
duloxetine hydrochloride
1208.10
NCT02232555
Depressive Disorder, Major
Phase 3
 
The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.
January 2015